London, United Kingdom – 1 September 2024: An invasive strategy vs. optimal medical therapy alone after a non-ST-elevation myocardial infarction (NSTEMI) in older adults did not affect the combined ...

An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction that has been treated with guideline-recommended complete ...

LONDON -- Routine coronary intervention was safe and somewhat beneficial for older people with non-ST-segment elevation myocardial infarction (NSTEMI) in the SENIOR-RITA trial, unique for being ...

The benefit of complete revascularization in older patients (≥75 years of age) with myocardial infarction and multivessel disease remains unclear. In this multicenter, randomized trial, we assigned ...

Medical Management/Treatment Initial treatment for suspected STEMI and NSTEMI requires a loading dose of nonenteric coated ASA at 162 to 325 mg (unless contraindicated), nitroglycerin in response to ...

Among patients presenting to the hospital with NSTEMI, an early invasive strategy based on symptom-to-catheter time is associated with a lower risk of all-cause mortality at 3 years, according to new ...

The vast majority of patients presenting with type 1 NSTEMI undergo invasive coronary angiography in the US, with most receiving PCI, according to an analysis presented this week at CRT 2026. But as ...

Brexogen has initiated clinical trials for its myocardial infarction treatment developed using its proprietary platform technology. On May 13, Brexog ...

The ISCHEMIA trial found no significant difference between an invasive vs. a conservative strategy in patients with chronic ...